Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-172154 with or without Azacitidine and Venetoclax in MDS or AML
NCT05275439Phase 1Terminated
- Sponsor
- Shattuck Labs
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of SL-172154 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Shattuck Labs. Primary endpoints: Safety Profile of SL-172154 Monotherapy or in Combination With Azacitidine, Recommended Phase 2 Dose of SL-172154 Administered With Azacitidine and 1 more. Started Mar 2022; status: terminated.
02
Drugs
SL-172154
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05275439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275439.